| 张鸽,吴雯雯,乔青,等.ICS和 LABA在气流受限嗜酸性粒细胞增多的稳定期支气管扩张症中的应用观察[J].安徽医药,2026,30(10):2095-2100. |
| ICS和 LABA在气流受限嗜酸性粒细胞增多的稳定期支气管扩张症中的应用观察 |
| Clinical application of ICS+LABA in patients with stable bronchiectasis and airflow limitation accompanied by eosinophilic elevation |
| |
| DOI：10.3969/j.issn.1009-6469.2026.10.036 |
| 中文关键词: 支气管扩张症 嗜酸性粒细胞增多 气流受限 布地奈德福莫特罗粉吸入剂 噻托溴铵 |
| 英文关键词: Bronchiectasis Eosinophils Airflow limitation Budesonide and Formoterol fumarate power for inhalation Tiotro-pium bromide |
| 基金项目: |
| 作者 | 单位 | E-mail | | 张鸽 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | | | 吴雯雯 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | | | 乔青 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | | | 郑涛 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | | | 高顺翠 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | | | 张艳 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | | | 李洁月 | 济南市第五人民医院职能管理部门,山东济南 250000 | | | 苏琳 | 济南市第四人民医院呼吸与危重症医学科,山东济南,250000 | 13969068817@163.com |
|
| 摘要点击次数: 102 |
| 全文下载次数: 27 |
| 中文摘要: |
| 目的观察吸入性糖皮质激素( ICS)+长效 β2受体激动剂( LABA)在气流受限的嗜酸性粒细胞增多的稳定期支气管扩张症中的临床应用效果。方法前瞻性研究。选取济南市第四人民医院 2022年 1月至 2023年 6月诊治的存在嗜酸性粒细胞增多的气流受限的稳定期支气管扩张症病人，随机分为观察组( 30例)对照组( 29例)对照组给予吸入长效 M胆碱受体阻断剂( LAMA)噻托溴铵治疗，观察组在噻托溴铵吸入治疗基础上给予ICS/LA，BA(布地奈德福，莫特罗粉吸入剂)吸入治疗，随访观察 1年，治疗和观察过程中共脱落 4例， 55例完成观察及随访。记录观察指标，进行统计学分析。结果吸入 ICS+LABA 1年后观察组圣乔治呼吸问卷( SGRQ)评分为( 43.714±16.964)分，对照组为( 53.074±11.809)分，观察组下降更明显。改良版英国医学研究委员会呼吸困难( mMRC)量表评分观察组较对照组有下降趋势。随访 12个月观察组急性加重的次数减少( P<0.05)。观察组与对照组经治疗后 FEV1、FEV1%pred比较，差异无统计学意义( P>0.05)声音嘶哑、白色念珠菌感染方面差异无统计学意义( P>0.05)。结论 ICS+LABA可提高嗜酸性粒细胞增多的具有气流受限的稳，定期支扩病人的治疗效果，改善病人的生活质量，减少 12个月急性加重事件的发生。 |
| 英文摘要: |
| Objective To observe the clinical application effect of inhaled glucocorticoids (ICS) combined with long-acting β2 ago-nist (LABA) in patients with stable bronchiectasis and airflow limitation with elevated-eosinophilia.Methods Prospective study. Thir-ty patients with bronchiectasis and airflow limitation with eosinophilia elevation diagnosed and treated at the Fourth People's Hospitalof Jinan from January 2022 to June 2023 were randomly divided into the observation group (30 cases) and the control group (29 cases).The control group was treated with a long-acting muscarinic antagonist (LAMA) tiotropium bromide inhalation, while the observationgroup received ICS/LABA (formoterol budesonide) inhalation in addition to tiotropium bromide inhalation. All patients were followedup for 1 year. During treatment and observation, 4 cases dropped out and 55 cases completed the observation and follow-up. The obser-vation indicators were recorded and statistically analyzed.Results After 1 year of treatment with inhaled ICS+LABA, the St. George'srespiratory questionnaire (SGRQ) score in the observation group and in the control group was (43.714±16.964)points and (53.074±11.809)points, respectively, with a more significant reduction observed in the observation group. The modified Medical Research Coun-cil (mMRC) dyspnea scale score showed a declining trend in the observation group compared with the control group. The number ofacute exacerbations in the observation group decreased over a 12-month follow-up, with statistically significant differences (P < 0.05). There was no statistically significant difference in FEV1 and FEV1% predicted between the observation group and the control group after treatment (P>0.05), hoarseness and the infection of candidiasis showed no statistically significant difference between the two groups (P> 0.05).Conclusion ICS + LABA can improve the treatment effect of patients with stable period bronchiectasis with airflow limitationand eosinophilia elevation, improve the quality of life of patients and reduce the occurrence of 12-month acute exacerbations. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
